Jazz Pharmaceuticals

The Competition Commission of Pakistan (CCP) is finalizing the PTCL-Telenor merger, a complex case with potential monopoly implications. The merger could enhance PTCL's dominance in upstream, midstream, and downstream telecom segments, affecting smaller players and consumer rights. CCP held hearings to assess market power, consumer impact, and long-term dynamics, with PTCL advocating for operational efficiency and competition enhancement. Opponents like Wateen Telecom fear a stifling of competition in infrastructure services. The CCP's decision will shape Pakistan's telecom future.

A federal judge ruled the FDA didn’t break orphan drug exclusivity by approving Avadel CNS Pharmaceuticals LLC’s Lumryz, a rival to Jazz Pharmaceuticals PLC’s Xywav.

The Competition Commission of Pakistan (CCP) is conducting a Phase II Merger Review of PTCL’s acquisition of Telenor Pakistan and Orion Towers, with five extensive hearings held so far. The CCP Bench, led by Chairman Dr Kabir Ahmed Sidhu, has posed critical questions on the merger’s impact, with PTCL addressing concerns over competitive benefits and potential risks. PTCL highlighted expected reductions in market share gaps, cost savings, and 5G service roll-out, while assuring compliance with the Spectrum Sharing Framework. Jazz and Wateen reiterated concerns over tariff regulations and infrastructure sharing. The CCP aims to fully address any competitive risks to safeguard market competition and consumer welfare.

Jazz Pharmaceuticals' Phase III IMforte study showed Zepzelca with Roche’s Tecentriq significantly boosts survival in extensive-stage small cell lung cancer patients. The combo regimen improved overall and progression-free survival, with a well-tolerated safety profile. Jazz plans to file a supplemental New Drug Application for Zepzelca in 2025, aiming for first-line maintenance therapy approval.

The Competition Commission of Pakistan (CCP) is reviewing PTCL’s acquisition of 100% shareholding in Telenor Pakistan and Orion Towers. The CCP is analyzing market power concentration, competitive dynamics, and merger impact, ensuring stakeholder involvement. Transworld Associates urged preventive and corrective remedies based on international practices. Telenor defended the transaction’s merits.

The Competition Commission of Pakistan (CCP) held its first Phase II Merger Review hearing on PTCL's acquisition of Telenor Pakistan and Orion Towers. The hearing, chaired by CCP Chairman Dr Kabir Ahmed Sidhu, included presentations from PTCL's senior management and Wateen Telecom Limited. The review, under Section 11(6) of the Competition Act 2010, assesses market share dynamics and concentration risks. The next hearing is set for October 2, 2024.

CCP held its first Phase II Merger Review hearing on PTCL's acquisition of Telenor Pakistan and Orion Towers, with PTCL emphasizing economic benefits. Wateen Telecom presented preliminary submissions. Next hearing scheduled for October 2, 2024.

I-DXd (ifinatamab deruxtecan) showed clinically meaningful responses in pretreated extensive-stage SCLC patients, with a confirmed response rate of 26.1% at 8 mg/kg and 54.8% at 12 mg/kg. The 12 mg/kg dose was selected as optimal for further study.